Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Gopal, Ramakrishnan"'
Autor:
Gopal Ramakrishnan Gopi, Nehru Ganesh, Suppuram Pandiaraj, Balasubramaniyam Sowmiya, Raman Gulab Brajesh, Subramanian Ramalingam
Publikováno v:
Food Technology and Biotechnology, Vol 53, Iss 3, Pp 331-336 (2015)
3-Hydroxypropionic acid (3-HP) is a novel antimicrobial agent against foodborne pathogens like Salmonella and Staphylococcus species. Lactobacillus reuteri converts glycerol into 3-HP using a coenzyme A-dependent pathway, which is encoded by propaned
Externí odkaz:
https://doaj.org/article/681712a12b5443298a382799e8d5d477
Autor:
H S Sandeepa, Preyas J Vaidya, Prashant N Chhajed, Gopal Ramakrishnan, Tejinder Paul Singh, Rajat Bhargava, S.K. Susheel Kumar
Publikováno v:
Journal of Cancer Research and Therapeutics, Vol 12, Iss 3, Pp 1198-1202 (2016)
Bleomycin is a cytostatic drug commonly employed in the treatment of Hodgkin's disease, seminomas, and choriocarcinoma. Bleomycin may induce a chronic pulmonary inflammation that may progress to fibrosis. So far, only corticosteroids have been used i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44a853342da1c58532bab89cf7b6919d
http://www.cancerjournal.net/article.asp?issn=0973-1482
http://www.cancerjournal.net/article.asp?issn=0973-1482
Publikováno v:
Bioscience, biotechnology, and biochemistry. 83(4)
The process economy of food grade 1,3-propanediol (1,3-PD) production by GRAS organisms like Lactobacillus reuteri (L. reuteri), is negatively impacted by the low yield and use of expensive feedstocks. In order to improve the process economy, we have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b78d8d244bf574ad5a5b16ce24593159
https://pubmed.ncbi.nlm.nih.gov/30582401
https://pubmed.ncbi.nlm.nih.gov/30582401
Autor:
Gopi, Gopal Ramakrishnan1 ramabioprocess@annauniv.edu, Ganesh, Nehru1, Pandiaraj, Suppuram1, Sowmiya, Balasubramaniyam1, Brajesh, Raman Gulab1, Ramalingam, Subramanian1
Publikováno v:
Food Technology & Biotechnology. Jul-Sep2015, Vol. 53 Issue 3, p331-336. 6p.
Autor:
Ganesh Nehru, Ramalingam Subramanian, Gopi Gopal Ramakrishnan, Sowmiya Balasubramaniyam, Pandiaraj Suppuram, Brajesh Raman Gulab
Publikováno v:
Current Microbiology. 71:517-523
Lactobacillus reuteri grown in MRS broth containing 20 mM glycerol exhibits 3.7-fold up-regulation of 3-hydroxypropionic acid (3-HP) pathway genes during the stationary phase. Concomitantly, the resting cells prepared from stationary phase show enhan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974da2172ee3528ebf1b36d946c9b698
https://doi.org/10.1007/s00284-015-0878-7
https://doi.org/10.1007/s00284-015-0878-7
Autor:
Gopal Ramakrishnan, Gopi, Nehru, Ganesh, Suppuram, Pandiaraj, Balasubramaniyam, Sowmiya, Raman Gulab, Brajesh, Subramanian, Ramalingam
Publikováno v:
Food technology and biotechnology. 53(3)
3-Hydroxypropionic acid (3-HP) is a novel antimicrobial agent against foodborne pathogens like Salmonella and Staphylococcus species. Lactobacillus reuteri converts glycerol into 3-HP using a coenzyme A-dependent pathway, which is encoded by propaned
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6afa65a6db3576aae5bf77d299f3645a
https://pubmed.ncbi.nlm.nih.gov/27904365
https://pubmed.ncbi.nlm.nih.gov/27904365
Autor:
R. G. Brajesh, Suppuram Pandiaraj, Nehru Ganesh, Gopal Ramakrishnan Gopi, Subramanian Ramalingam, Balasubramaniyam Sowmiya
Publikováno v:
Food Technology and Biotechnology, Vol 53, Iss 3, Pp 331-336 (2015)
Summary 3-Hydroxypropionic acid (3-HP) is a novel antimicrobial agent against foodborne pathogens like Salmonella and Staphylococcus species. Lactobacillus reuteri converts glycerol into 3-HP using a coenzyme A-dependent pathway, which is encoded by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8edb57f15a76411a8585915b039c756d
https://doi.org/10.17113/ftb.53.03.15.3976
https://doi.org/10.17113/ftb.53.03.15.3976
Autor:
Madhavan Krishnan Nair, Chandra Sekhar Rao, Ali Khojasteh, Karen Hoelzer, Youn C. Park, John Gutheil, Aruna Chandrasekharan, Katherine Tkaczuk, Troy H. Guthrie, Gopal Ramakrishnan, Gerald Batist, Pankaj Shah, Lily W. Lee
Publikováno v:
Journal of Clinical Oncology. 19:1444-1454
PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd50640f1d9855522b56cd24b6db0c47
https://doi.org/10.1200/jco.2001.19.5.1444
https://doi.org/10.1200/jco.2001.19.5.1444
Autor:
Purvish M. Parikh, C. S. Soman, Narendran N. Nair, Suresh H. Advani, Reena Nair, Gopal Ramakrishnan, Ketayun T. Dinshaw, Sandhaya R. Joshi, Maryann Mukhadan, Tapan K. Saikia
Publikováno v:
Cancer. 82:2282-2288
BACKGROUND Combination chemotherapy consisting of methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone, and bleomycin (MACOP-B) has been frequently used for the treatment of non-Hodgkin's lymphoma. This randomized study was undertak
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad93ba925577ed79aec93a0608943723
https://doi.org/10.1002/(sici)1097-0142(19980601)82:11<2282::aid-cncr26>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19980601)82:11<2282::aid-cncr26>3.0.co
Autor:
Gopal Ramakrishnan, Tapan K. Saikia, Hedge U, Prafulla B. Desai, Jagdeesh N. Kulkarni, Suresh H. Advani
Publikováno v:
Journal of Surgical Oncology. 51:100-103
Twenty-seven patients with metastatic nonseminomatous germ cell tumors were treated with Cisplatin, vinblastine, bleomycin, and low-dose meth-otrexate (PVB + M) combinations. Patients were divided into good-risk and poor-risk groups. All seven patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a176ffd4bd2d7420d2db1f4aced27883
https://doi.org/10.1002/jso.2930510207
https://doi.org/10.1002/jso.2930510207